61 lekarz wykonujący radioterapię raka odbytnicy

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr Yaacov Lawrence jest ordynatorem oddziału radioterapii onkologicznej w Centrum Medycznym Sheba. Specjalizuje się w precyzyjnej radioterapii i neuroonkologii. Dr Lawrence był pionierem radiochirurgii splotu trzewnego w leczeniu bólu w przebiegu raka trzustki. Posiada tytuł FASTRO, jedno z najwyższych wyróżnień w swojej specjalizacji.

• Kieruje programem leczenia nowotworów układu pokarmowego w Centrum Medycznym Sheba.
• Wykonuje radiochirurgię stereotaktyczną guzów mózgu i nowotworów układu nerwowego.
• Jest autorem ponad 280 publikacji naukowych na temat spersonalizowanych protokołów napromieniania.
• Ukończył staż specjalizacyjny (fellowship) z radioterapii onkologicznej na Uniwersytecie Thomasa Jeffersona.

Dr Ahn Jin Seok specjalizuje się w radioterapii raka jelita grubego w Samsung Medical Center.

• Onkolog z bogatym doświadczeniem w leczeniu raka jelita grubego
• Praktykuje w Samsung Medical Center – wiodącej placówce leczenia nowotworów

Onkolog specjalizujący się w radioterapii w Samsung Medical Center.

• Doświadczenie w leczeniu raka jelita grubego za pomocą radioterapii
• Pracuje w wiodącym centrum medycznym w Korei Południowej
• Koncentruje się na spersonalizowanych planach leczenia pacjentów

Profesor Lim Do Hoon kieruje oddziałem onkologii radiacyjnej w Samsung Medical Center, specjalizując się w nowotworach przewodu pokarmowego i rzadkich nowotworach.

• Szkolił się w szpitalu Seoul National University Hospital oraz Samsung Medical Center
• Specjalizuje się w nowotworach żołądka, trzustki i dróg żółciowych oraz nowotworach dziecięcych
• Ekspert w dziedzinie radioterapii w złożonych przypadkach żołądkowo-jelitowych
• Członek Koreańskiego Stowarzyszenia Onkologicznego oraz Koreańskiego Towarzystwa Onkologii Radiacyjnej

Dr Choi Du Kho specjalizuje się w operacjach serca i posiada ponad doświadczenia w Samsung Medical Center.

• Ekspert w kardiochirurgii wspomaganej robotycznie
• Specjalista w naprawie i wymianie zastawek
• Wykonuje operacje serca u dzieci

Prof. Miriam Ben-Harush jest uznanym na całym świecie specjalistą w dziedzinie onkologii dziecięcej i przeszczepów szpiku kostnego w Szpitalu Dziecięcym Ruth Rappaport.

• Dyrektor Oddziału Pediatrii w Centrum Medycznym Rambam
• Kawaler Orderu Legii Honorowej
• Uznana za jednego z najbardziej troskliwych lekarzy na świecie przez Światowe Stowarzyszenie Lekarzy
• Członek amerykańskiej grupy onkologii dziecięcej

Dr Raphael Pfeffer specjalizuje się w radioterapii raka jelita grubego w Centrum Medycznym Assuta.

• Onkolog i radiolog z podwójną specjalizacją
• Koncentruje się na precyzyjnym planowaniu leczenia radioterapią
• Pracuje w jednym z wiodących ośrodków medycznych w Izraelu

Dr Swietłana Załmanowa jest wyspecjalizowanym radioterapeutą w Centrum Medycznym Assuta, koncentrującą się na leczeniu raka jelita grubego i odbytnicy.

• Ekspertyza w precyzyjnym podawaniu radioterapii
• Pracuje w wiodącym centrum medycznym w Izraelu
• Zajmuje się tworzeniem spersonalizowanych planów leczenia

Prof. Tamer Atasever wnosi 34 lat doświadczenia w medycynie nuklearnej, w tym role kierownicze w czołowych tureckich instytucjach.

• Profesor w Szpitalu Uniwersyteckim Medipol i na Uniwersytecie Gazi
• Były dyrektor ds. medycyny nuklearnej w laboratorium Ankara Order
• Członek Europejskiego Towarzystwa Medycyny Nuklearnej
• Specjalizuje się w zaawansowanej diagnostycznej i terapeutycznej medycynie nuklearnej

Dr Raj przeprowadził ponad 50 000 operacji onkologicznych w ciągu _doctor_2241_lat_, specjalizując się w chirurgii onkologicznej piersi i klatki piersiowej w HCG Manavata Cancer Centre.

• Szkolił się w Tata Memorial Hospital oraz Royal College of Surgeons w Edynburgu
• Brał udział w ponad 200 badaniach klinicznych, w tym w badaniach fazy 1-3
• Profesor w dziedzinie chirurgii onkologicznej i chirurgii piersi (DNB Superspecialty)
• Koncentruje się na poprawie jakości życia pacjentów równolegle z leczeniem

Dr Shaunak specjalizuje się w terapiach celowanych w raku jelita grubego, a jego badania były prezentowane w American Society of Clinical Oncology.

• Szkolenie z onkologii medycznej w Indraprastha Apollo Hospital
• Ekspertyza w zakresie molekularnych podstaw nowotworów
• Prezentacja badań nad rakiem żołądka na ASCO
• Starsza rezydentura w Jawaharlal Nehru Cancer Hospital

Dr Lalit Banswal przeprowadził ponad 10 000 poważnych operacji w ciągu _doctor_2291_lat_ swojego doświadczenia, koncentrując się na nowotworach przewodu pokarmowego w HCG Manavata Cancer Centre.

• Odbył staż specjalizacyjny z onkologii chirurgicznej w Tata Medical Centre w Kalkucie
• Specjalizuje się w małoinwazyjnych operacjach onkologicznych z doskonałymi wynikami
• Były adiunkt w State Cancer Institute i Government Cancer Hospital w Aurangabadzie
• Opublikował liczne krajowe i międzynarodowe prace badawcze
• Znany z etycznego podejścia i dbałości o pacjenta

Dr Ahmer Arif Shaikh specjalizuje się w operacjach raka jamy ustnej, koncentrując się na zachowaniu narządów i rehabilitacji funkcjonalnej w HCG Manavata Cancer Centre.

• 15 lat doświadczenia w onkologii chirurgicznej
• Wyszkolony w ramach stypendium w zakresie chirurgii onkologicznej głowy i szyi
• Biegły w głównych operacjach szczękowo-twarzowych oraz głowy i szyi
• Badacz z licznymi publikacjami

Dr Shruti Kate specjalizuje się w immunoterapii i terapii metronomicznej w zaawansowanych nowotworach, a jej badania były prezentowane na Światowej Konferencji Raka Płuc.

• Szkoliła się w Tata Memorial Hospital – jednym z najlepszych ośrodków onkologicznych w Indiach
• Ekspertyza w zakresie nowotworów płuc, piersi, ginekologicznych i układu moczowo-płciowego
• Członek ASCO, ESMO i innych wiodących towarzystw onkologicznych
• Laureatka prestiżowej nagrody podróżnej na WCLC 2018

Dr Borde wykonał ponad 30 000 badań PET i leczył ponad 1000 pacjentów z rakiem tarczycy w HCG Manavata Cancer Centre.

• _doctor_2774_lat_ doświadczenia w medycynie nuklearnej
• Specjalizuje się w terapiach radiojodem i Lu-177
• Biegły we wszystkich rodzajach badań nuklearnych i obrazowaniu PET-CT
• Opublikował liczne artykuły w czasopismach medycznych

Dr Sridhar P.S. specjalizuje się w radioterapii raka jelita grubego w HCG Manavata Cancer Centre, posiadając ponad 30 lat ukierunkowanego doświadczenia w tej dziedzinie.

• Szkolenie z zakresu radioterapii na Banaras Hindu University
• Dyplomowany członek National Board w dziedzinie radioterapii
• Aktywny członek Association of Radiation Oncology of India
• Specjalizuje się w zaawansowanych technikach radioterapii w leczeniu nowotworów